BAY1082439
Cat. No.：YN420340
CAS No. ：1375469-38-7
| 产品名称: | BAY1082439 |
| CAS No.: | 1375469-38-7 |
| Chemical Name: | N-[2,3-dihydro-8-[(2R)-2-hydroxy-3-(4-morpholinyl)propoxy]-7-methoxyimidazo[1,2-c]quinazolin-5-yl]-2-methyl-3-pyridinecarboxamide |
| Synonyms: | BAY10-82439; BAY 10-82439; BAY-10-82439; BAY1082439; BAY 1082439; BAY-1082439 |
| 分子量: | 494.6 |
| 分子式: | C25H30N6O5 |
| SMILES: | COC1=C2C(C3=NCCN3C(NC(C4=C(N=CC=C4)C)=O)=N2)=CC=C1OC[C@H](O)CN5CCOCC5 |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | BAY1082439 是一种具有口服活性的，选择性PI3Kα/β/δ抑制剂。BAY1082439 也能抑制 PIK3CA 的突变形式，BAY1082439 对抑制Pten丢失的前列腺癌的生长有很强的作用。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Zou, Y., Qi, Z., Guo, W., et al.Cotargeting the cell-intrinsic and microenvironment pathways of prostate cancer by PI3Kα/β/δ inhibitor BAY1082439Mol. Cancer Ther.17(10),2091-2099(2018)
Qi, J., Xu, Z., Zhang, L., et al.Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatmentNat. Commun.13(1),182(2022)
